Qiagen has announced it has completed the acquisition of Verogen, a leader in the use of next-generation sequencing (NGS) technologies to drive the future of human identification (HID) and forensic investigation.
Verogen, a privately held company founded in 2017 and based in San Diego, supports the global human identification community with NGS tools and professional services. Qiagen and Verogen have been commercialization partners since announcing a distribution agreement in June 2021.
Qiagen – which in the late 1990s launched the first commercial kits to purify DNA from forensic casework samples – already has a leading position in the HID / forensics market. Qiagen‘s sample collection and preparation kits, genetic testing analysis, and workflow automation products are used around the world by forensic science laboratories.
“We are proud to take our successful partnership with Qiagen to the next level in a combination that we believe creates significant advantages for all stakeholders,” said Brett Williams, CEO of Verogen. “This step will expand the value of Verogen’s portfolio to forensics customers and investigative agencies, and further drive the adoption of NGS to foster advances in justice worldwide.
